title: The association of ICAM-1 Exon 6 (E469K) but not of ICAM-1 Exon 4 (G241R) and PECAM-1 Exon 3 (L125V) polymorphisms with the development of differentiation syndrome in acute promyelocytic leukemia.
abstract: The use of all trans-retinoic acid (ATRA) is the basis of treatment of acute promyelocytic leukemia (APL) and represents the paradigm of differentiation therapy. In general, ATRA is well-tolerated but may be associated with a potentially lethal side-effect, referred to as retinoic acid or differentiation syndrome (DS). The cellular and molecular mechanisms of DS are poorly understood and involve changes in the adhesive qualities and cytokine secretion of leukemic cells during ATRA-induced differentiation. As leukocyte extravasation is a key event in DS pathogenesis, we analyzed the association between the polymorphisms at Exon 4 (G241R) and Exon 6 (E469K) of ICAM-1 and Exon 3 (L125V) of PECAM-1 genes with DS development in APL patients treated with ATRA and anthracyclines. DS was diagnosed in 23/127 (18.1%) APL patients at an average of 11.5 days after the start of ATRA. All patients presented respiratory distress associated with increased ground-glass opacity in chest radiographies. Other accompanying symptoms were: fever not attributable to infection (65.2%), generalized edema (37.5%), weight gain (37.5%), and impairment of renal function (8.6%). We detected an association between development of DS and the AA genotype at Codon 469 of ICAM-1 (odds ratio of 3.5; 95% confidence interval: 1.2-10.2). Conversely, no significant association was detected between G241R or L125V polymorphisms at Exon 4 of ICAM-1 and Exon 3 of PECAM-1, respectively. Our results suggest that susceptibility to DS in APL patients may be influenced by genetic variation in adhesion molecule loci.
authors: Hematology Division, Department of Internal Medicine, Medical School of Ribeirão Preto, University of São Paulo, Av Bandeirantes 3900, CEP 14048-900, Ribeirão Preto, SP, Brazil.
authors: Adriana I
authors: AI
authors: Dore
authors: Barbara A A
authors: BA
authors: Santana-Lemos
authors: Virginia M
authors: VM
authors: Coser
authors: Flávia L S
authors: FL
authors: Santos
authors: Leandro F
authors: LF
authors: Dalmazzo
authors: Ana S G
authors: AS
authors: Lima
authors: Rafael H
authors: RH
authors: Jacomo
authors: Jorge
authors: J
authors: Elias
authors: Roberto Passetto
authors: RP
authors: Falcão
authors: Waldir V
authors: WV
authors: Pereira
authors: Eduardo M
authors: EM
authors: Rego
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects; D002454:Cell Differentiation; D003937:Diagnosis, Differential; D005091:Exons / Q000235:genetics*; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000235:genetics*; D015473:Leukemia, Promyelocytic, Acute / Q000150:complications / Q000175:diagnosis / Q000235:genetics*; D008297:Male; D019408:Platelet Endothelial Cell Adhesion Molecule-1 / Q000235:genetics*; D011110:Polymorphism, Genetic / Q000235:genetics*; D013577:Syndrome; D014212:Tretinoin / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D019408:Platelet Endothelial Cell Adhesion Molecule-1; D018799:Intercellular Adhesion Molecule-1; D014212:Tretinoin